Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2010 1
2011 1
2013 1
2015 1
2016 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy.
Ingrasciotta Y, Fontana A, Mancuso A, Ientile V, Sultana J, Uomo I, Pastorello M, Calabrò P, Andò G, Trifirò G. Ingrasciotta Y, et al. Among authors: uomo i. Pharmaceuticals (Basel). 2021 Mar 25;14(4):290. doi: 10.3390/ph14040290. Pharmaceuticals (Basel). 2021. PMID: 33805899 Free PMC article.
In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study.
Ingrasciotta Y, Belleudi V, Trotta F, Addis A, Fontana A, Chinellato A, Ientile V, Tari DU, Roberto G, Pastorello M, Scondotto S, Cananzi P, Traversa G, Davoli M, Rossi M, Trifirò G; Italian Biosimilars Network (I-BioNetwork). Ingrasciotta Y, et al. BioDrugs. 2020 Feb;34(1):55-64. doi: 10.1007/s40259-019-00385-y. BioDrugs. 2020. PMID: 31595485
Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
Belleudi V, Trotta F, Addis A, Ingrasciotta Y, Ientile V, Tari M, Gini R, Pastorello M, Scondotto S, Cananzi P, Traversa G, Davoli M, Trifirò G; Italian Biosimilar Network (ItaBioNet). Belleudi V, et al. Drug Saf. 2019 Dec;42(12):1437-1447. doi: 10.1007/s40264-019-00845-y. Drug Saf. 2019. PMID: 31228010 Free PMC article.
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.
Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, Troncone C, Fontana A, Ientile V, Gini R, Santoro D, Santarpia M, Genazzani A, Uomo I, Pastorello M, Addario WS, Scondotto S, Cananzi P, Caputi AP, Trifirò G. Ingrasciotta Y, et al. Among authors: uomo i. BioDrugs. 2015 Aug;29(4):275-84. doi: 10.1007/s40259-015-0132-7. BioDrugs. 2015. PMID: 26169209 Free PMC article.
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
Marcianò I, Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Di Giorgio A, Manna S, Ientile V, Gini R, Santarpia M, Genazzani AA, Uomo I, Pastorello M, Pollina Addario SW, Scondotto S, Cananzi P, Da Cas R, Traversa G, Rossi M, Sottosanti L, Caputi AP, Trifirò G. Marcianò I, et al. Among authors: uomo i. BioDrugs. 2016 Aug;30(4):295-306. doi: 10.1007/s40259-016-0175-4. BioDrugs. 2016. PMID: 27138636